Group 1 - The core point of the article highlights that Huakang Biomedical (08622) has seen a significant stock deposit by shareholders into Zhonghao Securities, with a market value of HKD 49.5083 million, representing 24.13% of the total [1] - On August 15, Huakang Biomedical reported its financial results for the six months ending June 30, 2025, showing revenue of RMB 12.329 million, a year-on-year increase of 3.4% [1] - The company experienced a net loss of RMB 2.369 million, which is a 33.2% increase in losses compared to the previous year, with a basic loss per share of 0.47 cents [1] Group 2 - The increase in revenue is attributed to higher sales of male infertility in vitro diagnostic reagents and a series of parasitic testing reagents during the reporting period [1]
华康生物医学股东将股票存入中昊证券 存仓市值4950.83万港元